Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis

Table 1

Incremental cost-effectiveness ratios between adalimumab treatment and no adalimumab treatment but instead ongoing medical treatment.

Time horizon	Utility score of response with ADA measured by time trade-off ()	Utility score of response with ADA measured by visual rating scale ()
5 years	$45,000 ($25,000–$65,000)	$40,000 ($22,000–$58,000)
10 years	$59,000 ($37,000–$81,000)	$53,000 ($33,000–$72,000)
15 years	$68,000 ($45,000–$91,000)	$60,000 ($40,000–$81,000)

= utility score for the response to adalimumab health state.